The Patent 1000 focuses exclusively on patent practice and has firmly established itself as the definitive 'go-to' resource for those seeking world-class legal patent expertise.
Bronze - Individuals: litigation
Osborne Clarke is one of the fastest-growing names on the UK patent litigation market, its profile having enlarged massively in recent years. This is in large part thanks to its involvement in the hot-topic Unwired Planet dispute in the telecommunications field, but it has also sought to increase its life sciences capabilities too, by bringing in specialist solicitors Will James and Chris Pratt in 2019, and Tim Harris in 2020. James and Pratt have together tackled a complex multi-jurisdictional case on behalf of Amgen against Sanofi and Regeneron – James is reportedly “well-versed in international coordination and absolutely trusted by clients”, while Pratt has an exhaustive knowledge of chemistry and brings a history of acting in SPC litigation for the likes of Pfizer and AstraZeneca. Heading up the IP department is Arty Rajendra, who specialises in SEP and FRAND disputes and is known for her involvement in the Unwired Planet v Huawei case. “Arty is well-versed in UK law, both from a historical context and her continuing efforts to support the strategic development of new case law as a result of her recent litigationsuccesses.”
Tim Harris is a partner in Osborne Clarke’s IP disputes team in the United Kingdom. He has extensive experience advising on IP strategy, and enforcing and defending IP rights. He also helps clients to understand their IP risks, and to exploit and monetise their IPassets.
Mr Harris’s practice is focused on the life sciences and healthcare sector. He has advised on numerous blockbuster pharmaceuticals and biotech treatments, including a number of monoclonal antibodytherapies.
As well as being involved with UK patent litigation, Mr Harris works frequently on IP disputes that require a multi-jurisdictional team and enjoys the challenge of designing and deploying creative legal and commercialstrategies.
Mr Harris has a first-class degree in chemistry from Oxford University and has been recognised as a ‘next generation’ lawyer in pharma and biotech by The Legal 500. He is a member of the European Patent Lawyers Association and the International Association for the Protection of Intellectual Property, and co-chairs the Biotech Litigation Subcommittee of the American Intellectual Property LawyersAssociation.
Mr Harris often speaks about IP issues to an international audience, including at the Technology Transfer Summit, Life Sciences IP Minds Conference and London IP Summit. He has also taught IP topics at The Oxford Said Business School, at a Cambridge University IP summer school and for Oxford University’s postgraduate IPdiploma.
Osborne Clarke is a future-focused international legal practice: across our well-connected network, we have over 900 talented lawyers and more than 270 expert partners based in 26 international locations around the world (with services in India being provided by a relationship firm). Our expertise in eight core sectors is focused on helping our clients to succeed in tomorrow’s world. Through our collaborative culture and sector-led approach, we have a robust understanding of the local business environment and in-depth legal expertise in each jurisdiction. We’re listeners, innovators and problem solvers, finding new ways to join the dots between our clients’ challenges today and the opportunities being created in an ever-evolving, ever-developing global society.
Our core sectors: life sciences and healthcare; media and comms tech; energy and utilities; financial services; real estate and infrastructure; workforce solutions; retail and consumer; and transport and automotive.
Osborne Clarke is the business name for an international legal practice and its associated businesses. Full details at www.osborneclarke.com/verein.
Our IP practice
We pride ourselves in acting for clients for whom intellectual property is an important and valuable part of their business. Our all-round experience means we can help clients protect, manage, enforce and exploit their intellectual property.
Many of the world’s leading companies come to us for IP advice, whether that’s litigation to enforce their intellectual property or defend them against third parties, freedom to operate or protecting their portfolio of brands. We always advise in the context of our clients’ business and our sector experience underpins that.
We regularly work with global companies to devise the most effective pan-European IP strategies, and with offices in six key European jurisdictions we can act locally to help you implement, exploit and enforce IP rights wherever appropriate.
Our patent specialists cover the full range of technologies with particular expertise in pharmaceuticals, biotechnology, medical devices, mobile telephony, electrical engineering, semiconductors and computer-implemented inventions.
We have helped leading technology companies manage and enforce their patent rights in the European Union. With specialists in the strategically important jurisdictions of the United Kingdom and Germany, we are on the spot in the cities where patent disputes are most likely to be fought. In all cases, we draw upon the technical and legal knowledge our lawyers have built up in this specialist area.
We also advise on the registrability of inventions in Europe, including appropriate and cost-effective strategies in the European Patent Office (EPO). We can also assist if you wish to license, acquire or dispose of patent rights, and assess a market opportunity. We have particular experience of FRAND licensing issues relating to standard-essential patents.
The practice is comprehensive in scope but is particularly known for acting in high-profile, high-value patent litigation, routinely involving an international element, as well as handling portfolio management matters for internationally recognised brands. We have acted in patent disputes in the English High Court, Court of Appeal, UK Supreme Court, EPO and UK Intellectual Property Office and the patent chambers of the courts in Düsseldorf, Munich, Hamburg, Manheim and Braunschweig, as well as the EPO and Federal Patent Court in cooperation with specialist external patent attorneys from the firm’s network.
We have extensive experience in a number of sectors, including life sciences (eg, Amgen, Morphosys and the German Cancer Research Institute), telecoms/FRAND (eg, Unwired Planet and PanOptis), mechanical (eg, PopSockets, ARMOR, Deutsche Windtechnik) and electronics/media and communications (eg, Infobip), in part reflecting our sector strengths as a whole and underpinning how we can bring to bear a range of ancillary services to support our clients.
With high-profile cases such as advising on Unwired Planet v Huawei and acting in the Olanzapine and PCSK9 litigation, Osborne Clarke has demonstrated clearly its ability to operate at the highest level of the German, UK and international patent field. We do so through a team which has outgrown the scale of some of the firms already ranked by IAM Patent 1000.
Osborne Clarke is also advising on patent licensing and IP-related matters in high-profile transactions such as the acquisition of Flender from Siemens AG.